- Tytuł:
- Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety, Addiction and Withdrawal.
- Autorzy:
- Źródło:
- Clinical drug investigation [Clin Drug Investig] 2021 Oct; Vol. 41 (10), pp. 835-842. Date of Electronic Publication: 2021 Aug 18.
- Typ publikacji:
- Journal Article; Review
- Język:
- English
- Imprint Name(s):
-
Publication: Auckland : Adis, Springer International
Original Publication: Mairangi Bay, Auckland, N.Z. ; Philadelphia : Adis International, c1995- - MeSH Terms:
-
Phobic Disorders*
Steroids*
Humans - References:
-
Thomas M, Wong CC, Anderson P, Grills N. Magnitude, characteristics and consequences of topical steroid misuse in rural North India: an observational study among dermatology outpatients. BMJ Open. 2020;10(5):e032829. (PMID: 32430446723952910.1136/bmjopen-2019-032829)
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15 (quiz 16–8). (PMID: 1638475110.1016/j.jaad.2005.01.010)
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153(10):1036–42. (PMID: 2872412810.1001/jamadermatol.2017.2437)
Stalder J-F, Aubert H, Anthoine E, Futamura M, Marcoux D, Morren M-A, et al. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. Allergy. 2017;72(11):1713–9. (PMID: 2843989610.1111/all.13189)
Choi E, Tan KW, Tang F, Tan C, Chandran NS. Efficacy of targeted education in reducing topical steroid phobia: a randomized clinical trial. J Am Acad Dermatol. 2020;83(6):1681–7. (PMID: 3217181510.1016/j.jaad.2020.02.079)
Choi E, Chandran NS, Tan C. Corticosteroid phobia: a questionnaire study using TOPICOP score. Singapore Med J. 2020;61(3):149–53. (PMID: 32488277790511610.11622/smedj.2019110)
Saito-Abe M, Futamura M, Yamamoto-Hanada K, Yang L, Suzuki K, Ohya Y. Topical corticosteroid phobia among caretakers of children with atopic dermatitis: a cross-sectional study using TOPICOP in Japan. Pediatr Dermatol. 2019;36(3):311–6. (PMID: 3088294610.1111/pde.13784)
Hon KL, Leong KF, Leung TN, Leung AK. Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices. Drugs Context. 2018;7:212547. (PMID: 305327926281040)
Hon K-LE, Leung TF, Yau HC, Chan T. Paradoxical use of oral and topical steroids in steroid-phobic patients resorting to traditional Chinese medicines. World J Pediatr. 2012;8(3):263–7. (PMID: 2288620210.1007/s12519-012-0369-x)
Hajar T, Leshem YA, Hanifin JM, Nedorost ST, Lio PA, Paller AS, et al. A systematic review of topical corticosteroid withdrawal (‘steroid addiction’) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-549.e2. (PMID: 2559262210.1016/j.jaad.2014.11.024)
Hwang J, Lio PA. Topical corticosteroid withdrawal ('steroid addiction’): an update of a systematic review. J Dermatolog Treat. 2021;4:1–6. (PMID: 10.1080/09546634.2021.1882659)
Rapaport MJ, Rapaport V. The red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev Dermatol. 2006;1(4):547–61. (PMID: 10.1586/17469872.1.4.547)
Ghosh A, Sengupta S, Coondoo A, Jana AK. Topical corticosteroid addiction and phobia. Indian J Dermatol. 2014;59(5):465–8. (PMID: 25284851417191410.4103/0019-5154.139876)
Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol. 1979;18(1):23–31. (PMID: 15389110.1111/j.1365-4362.1979.tb01905.x)
Fukaya M, Sato K, Sato M, Kimata H, Fujisawa S, Dozono H, et al. Topical steroid addiction in atopic dermatitis. Drug Healthc Patient Saf. 2014;14(6):131–8. (PMID: 10.2147/DHPS.S69201)
Sheary B. Steroid withdrawal effects following long-term topical corticosteroid use. Dermatitis. 2018;29(4):213–8. (PMID: 2992385210.1097/DER.0000000000000387)
Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol. 1999;41(3 Pt 1):435–42. (PMID: 1045911910.1016/S0190-9622(99)70118-0)
Lahiri K, Coondoo A. Topical steroid damaged/dependent face (TSDF): an entity of cutaneous pharmacodependence. Indian J Dermatol. 2016;61(3):265–72. (PMID: 27293246488517810.4103/0019-5154.182417)
Pal D, Biswas P, Das S, De A, Sharma N, Ansari A. Topical Steroid Damaged/Dependent Face (TSDF): a Study from a Tertiary Care Hospital in Eastern India. Indian J Dermatol. 2018;63(5):375–9. (PMID: 30210157612422410.4103/ijd.IJD_218_17)
Rapaport MJ, Rapaport V. Prolonged erythema after facial laser resurfacing or phenol peel secondary to corticosteroid addiction. Dermatol Surg. 1999;25(10):781–4 (discussion 785). (PMID: 1059457910.1046/j.1524-4725.1999.99097.x)
Jain S, Mohapatra L, Mohanty P, Jena S, Behera B. Study of clinical profile of patients presenting with topical steroid-induced facial dermatosis to a Tertiary Care Hospital. Indian Dermatol Online J. 2020;11(2):208–11. (PMID: 324779807247645)
Bhat YJ, Manzoor S, Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol. 2011;56(1):30–2. (PMID: 21572787308893010.4103/0019-5154.77547)
Juhász MLW, Curley RA, Rasmussen A, Malakouti M, Silverberg N, Jacob SE. Systematic review of the topical steroid addiction and topical steroid withdrawal phenomenon in children diagnosed with atopic dermatitis and treated with topical corticosteroids. J Dermatol Nurses’ Assoc. 2017;9(5):233–40. (PMID: 10.1097/JDN.0000000000000331)
Narang T, Kumaran MS, Dogra S, Saikia UN, Kumar B. Red scrotum syndrome: idiopathic neurovascular phenomenon or steroid addiction? Sex Health. 2013;10(5):452–5. (PMID: 2402882810.1071/SH13052)
Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48(2):181–3. (PMID: 602068210.1038/jid.1967.29)
Sheary B, Harris MF. Cessation of long-term topical steroids in adult atopic dermatitis: a prospective cohort study. Dermatitis. 2020;31(5):316–20. (PMID: 3240462110.1097/DER.0000000000000602)
Nnoruka E, Okoye O. Topical steroid abuse: its use as a depigmenting agent. J Natl Med Assoc. 2006;98(6):934–9. (PMID: 167759162569367)
Xiao X, Xie H, Jian D, Deng Y, Chen X, Li J. Rebounding triad (severe itching, dryness and burning) after facial corticosteroid discontinuation defines a specific class of corticosteroid-dependent dermatitis. J Dermatol. 2015;42(7):697–702. (PMID: 2587550210.1111/1346-8138.12877)
Sneddon I. Adverse effect of topical fluorinated corticosteroids in rosacea. Br Med J. 1969;1(5645):671–3. (PMID: 423768210.1136/bmj.1.5645.670)
Rathi SK, Kumrah L. Topical corticosteroid-induced rosacea-like dermatitis: a clinical study of 110 cases. Indian J Dermatol Venereol Leprol. 2011;77(1):42–6. (PMID: 2122087810.4103/0378-6323.74974)
Zheng P, Lavker RM, Lehmann P, Kligman AM. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Investig Dermatol. 1984;82(4):345–52. (PMID: 636870110.1111/1523-1747.ep12260665)
Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. (PMID: 23213332350857810.1155/2012/561018)
Croxtall JD, van Hal PTW, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol. 2002;135(2):511–9. (PMID: 11815387157313910.1038/sj.bjp.0704474)
Kirby JD, Munro DD. Steroid-induced atrophy in an animal and human model. Br J Dermatol. 1976;94(suppl 12):111–9. (PMID: 126807110.1111/j.1365-2133.1976.tb02279.x)
Marks R, Sawyer M. Glucocorticoid-induced vasoconstriction in human skin: an inhibitory role on phospholipase A2 activity. Arch Dermatol. 1986;122(8):881–3. (PMID: 287477310.1001/archderm.1986.01660200053013)
Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf. 2015;38(5):493–509. (PMID: 2586202410.1007/s40264-015-0287-7)
Lin T-K, Wei K-J, Wu C-H, Lai F-J, Lan C-CE, Chang C-H, et al. Barrier abnormalities and keratinocyte-derived cytokine cascade after cessation of long-term topical glucocorticosteroid on hairless mouse skin. Dermatol Sin. 2015;33(2):103–11. (PMID: 10.1016/j.dsi.2015.05.002)
Lubach D, Rath J, Kietzmann M. Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. Dermatology. 1995;190(1):51–5. (PMID: 789409810.1159/000246635)
Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05 % shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol. 2006;5(4):328–32. (PMID: 16673799)
Serup J, Holm P. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. Dermatologica. 1985;170(4):189–94. (PMID: 388870810.1159/000249529)
Cossmann M, Welzel J. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial. Br J Dermatol. 2006;155(4):700–6. (PMID: 1696541810.1111/j.1365-2133.2006.07369.x)
Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 2001;7(2):73–7. (PMID: 1139320710.1034/j.1600-0846.2001.70203.x)
du Vivier A, Phillips H, Hehir M. Applications of glucocorticosteroids: the effects of twice-daily vs once-every-other-day applications on mouse epidermal cell DNA synthesis. Arch Dermatol. 1982;118(5):305–8. (PMID: 708202010.1001/archderm.1982.01650170019014)
du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol. 1976;112(9):1245–8. (PMID: 99930010.1001/archderm.1976.01630330015002)
du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111(5):581–3. (PMID: 113080210.1001/archderm.1975.01630170039002)
Singh S, Gupta A, Pandey SS, Singh G. Tachyphylaxis to histamine-induced wheal suppression by topical 0.05% clobetasol propionate in normal versus croton oil-induced dermatitic skin. Dermatology. 1996;193(2):121–3. (PMID: 888414710.1159/000246225)
Bigas J, Sevilla LM, Carceller E, Boix J, Pérez P. Epidermal glucocorticoid and mineralocorticoid receptors act cooperatively to regulate epidermal development and counteract skin inflammation. Cell Death Dis. 2018;9(6):1–14. (PMID: 10.1038/s41419-018-0673-z)
Vandevyver S, Dejager L, Libert C. Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr Rev. 2014;35(4):671–93. (PMID: 2493770110.1210/er.2014-1010)
Sevilla L, Latorre V, Sanchis A, Perez P. Epidermal inactivation of the glucocorticoid receptor triggers skin barrier defects and cutaneous inflammation. J Invest Dermatol. 2012;6:133.
Burnstein KL, Jewell CM, Sar M, Cidlowski JA. Intragenic sequences of the human glucocorticoid receptor complementary DNA mediate hormone-inducible receptor messenger RNA down-regulation through multiple mechanisms. Mol Endocrinol. 1994;8(12):1764–73. (PMID: 7708063)
Pujols L, Mullol J, Pérez M, Roca-Ferrer J, Juan M, Xaubet A, et al. Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol. 2001;24(1):49–57. (PMID: 1115265010.1165/ajrcmb.24.1.4024)
Hägg PM, Hurskainen T, Palatsi R, Ilves M, Oikarinen A. Increased expression of glucocorticoid receptor beta in lymphocytes of patients with severe atopic dermatitis unresponsive to topical corticosteroid. Br J Dermatol. 2010;162(2):318–24. (PMID: 1990317610.1111/j.1365-2133.2009.09518.x)
Fukaya M. Cortisol homeostasis in the epidermis is influenced by topical corticosteroids in patients with atopic dermatitis. Indian J Dermatol. 2017;62(4):440. (PMID: 28794569552773910.4103/ijd.IJD_702_16)
Fukaya M. Histological and immunohistological findings using anti-cortisol antibody in atopic dermatitis with topical steroid addiction. Dermatol Ther (Heidelb). 2016;6(1):39–46. (PMID: 26838582479903810.1007/s13555-016-0096-7)
Stoughton RB. Bioassay system for formulations of topically applied glucocorticosteroids. Arch Dermatol. 1972;106(6):825–7. (PMID: 463924610.1001/archderm.1972.01620150011002)
Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2(1):1–12. (PMID: 1532082810.2174/1570161043476483)
Rapaport MJ, Rapaport VH. Serum nitric oxide levels in ‘red’ patients: separating corticosteroid-addicted patients from those with chronic eczema. Arch Dermatol. 2004;140(8):1013–4. (PMID: 1531382710.1001/archderm.140.8.1013)
Gokhale NR, Belgaumkar VA, Pandit DP, Deshpande S, Damle DK. A study of serum nitric oxide levels in psoriasis. Indian J Dermatol Venereol Leprol. 2005;71(3):175–8. (PMID: 1639440610.4103/0378-6323.16232)
Akdeniz N, Aktaş A, Erdem T, Akyüz M, Özdemir Ş. Nitric oxide levels in atopic dermatitis. Pain Clin. 2004;16(4):401–5. (PMID: 10.1163/1568569042664521)
Muijsers RB, Folkerts G, Henricks PA, Sadeghi-Hashjin G, Nijkamp FP. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci. 1997;60(21):1833–45. (PMID: 915499310.1016/S0024-3205(96)00651-0)
Moilanen E, Vapaatalo H. Nitric oxide in inflammation and immune response. Ann Med. 1995;27(3):359–67. (PMID: 754662610.3109/07853899509002589)
Guttman-Yassky E, Gallo RL, Pavel AB, Nakatsuji T, Li R, Zhang N, et al. A nitric oxide-releasing topical medication as a potential treatment option for atopic dermatitis through antimicrobial and anti-inflammatory activity. J Invest Dermatol. 2020;140(12):2531-2535.e2. (PMID: 3242854310.1016/j.jid.2020.04.013)
Hyun E, Bolla M, Steinhoff M, Wallace JL, del Soldato P, Vergnolle N. Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004;143(5):618–25. (PMID: 15313880157542210.1038/sj.bjp.0705854)
Kao JS, Fluhr JW, Man M-Q, Fowler AJ, Hachem J-P, Crumrine D, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120(3):456–64. (PMID: 1260386010.1046/j.1523-1747.2003.12053.x)
Matura M, Goossens A. Contact allergy to corticosteroids. Allergy. 2000;55(8):698–704. (PMID: 1095569410.1034/j.1398-9995.2000.00121.x)
Sheary B. Topical steroid withdrawal: a case series of 10 children. Acta Derm Venereol. 2019;99(6):551–6. (PMID: 3073404710.2340/00015555-3144)
Arnold KA, Treister AD, Lio PA. Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: a retrospective case series. JAAD Case Rep. 2018;4(9):860–2. (PMID: 30306110617244110.1016/j.jdcr.2018.06.012)
Berger T, Francis-Lyon P, Parker J, Friedman P, Sengar P, Owens J. Analysis of patient-reported symptoms with respect to TCS usage: a self-identified cohort of patients with RSS/TSA/TSW. J Am Acad Dermatol. 2017;76(6):AB44.
Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology. 1996;34(1):9–13. (PMID: 8739860)
Higgitt A, Fonagy P, Lader M. The natural history of tolerance to the benzodiazepines. Psychol Med Monogr Suppl. 1988;13:1–55. (PMID: 290851610.1017/S0264180100000412)
McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2):57–62. (PMID: 24868486402332510.4292/wjgpt.v5.i2.57)
Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, et al. Tachyphylaxis in major depressive disorder: a review of the current state of research. J Affect Disord. 2019;15(245):488–97. (PMID: 10.1016/j.jad.2018.10.357)
Forte WCN, Sumita JM, Rodrigues AG, Liuson D, Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr). 2005;33(6):307–11. (PMID: 10.1016/S0301-0546(05)73248-1)
National Eczema Society, British Association of Dermatologists. National Eczema Society and British Association of Dermatologists joint position statement on Topical Steroid Withdrawal [Internet]. 2021. https://eczema.org/wp-content/uploads/Topical-Steroid-Withdrawal-position-statement.pdf . Accessed 31 Jan 2021.
Kawakami T, Soma Y, Morita E, Koro O, Yamamoto S, Nakamura K, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology. 2001;203(1):32–7. (PMID: 1154979710.1159/000051700)
Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas J Dermatol. 2018;59(3):e168–74. (PMID: 29411351609928410.1111/ajd.12762)
Norsgaard H, Kurdykowski S, Descargues P, Gonzalez T, Marstrand T, Dünstl G, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–29. (PMID: 25027750416802110.1007/s00403-014-1485-3)
Frankel A, Sohn A, Patel RV, Lebwohl M. Bilateral comparison study of pimecrolimus cream 1 % and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. J Drugs Dermatol. 2011;10(6):666–72. (PMID: 21637908)
Fukaya M, Kimata H. Topical clofibrate improves symptoms in patients with atopic dermatitis and reduces serum TARC levels: a randomized, double-blind, placebo-controlled pilot study. J Drugs Dermatol. 2014;13(3):259–63. (PMID: 24595568)
Sheu HM, Lee JY, Kuo KW, Tsai JC. Permeability barrier abnormality of hairless mouse epidermis after topical corticosteroid: characterization of stratum corneum lipids by ruthenium tetroxide staining and high-performance thin-layer chromatography. J Dermatol. 1998;25(5):281–9. (PMID: 964088010.1111/j.1346-8138.1998.tb02399.x)
Hettmannsperger U, Tenorio S, Orfanos CE, Detmar M. Corticosteroids induce proliferation but do not influence TNF- or IL-1 beta-induced ICAM-1 expression of human dermal microvascular endothelial cells in vitro. Arch Dermatol Res. 1993;285(6):347–51. (PMID: 810575510.1007/BF00371835)
Kligman AM. Letter: topical steroid addicts. JAMA. 1976;235(15):1550. (PMID: 94626510.1001/jama.1976.03260410014003)
Colomb D. Stellate spontaneous pseudoscars. Senile and presenile forms: especially those forms caused by prolonged corticoid therapy. Arch Dermatol. 1972;105(4):551–4. (PMID: 501726510.1001/archderm.1972.01620070023008)
Adam JE, Craig G. Striae and their relation to topical steroid therapy. Can Med Assoc J. 1965;92(6):289–91. (PMID: 142702141927922)
Shuster S. The cause of striae distensae. Acta Derm Venereol Suppl (Stockh). 1979;59(85):161–9. (PMID: 294092)
Nigam PK. Striae cutis distensae. Int J Dermatol. 1989;28(7):426–8. (PMID: 267404110.1111/j.1365-4362.1989.tb02497.x)
Friedman SJ, Butler DF, Pittelkow MR. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. Report of two cases and review of the literature. J Am Acad Dermatol. 1988;19(3):537–41. (PMID: 304969910.1016/S0190-9622(88)70209-1)
Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989;62(5):375–91. (PMID: 2655506)
Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs. 1988;36(Suppl 5):15–23. (PMID: 307612910.2165/00003495-198800365-00005)
Dolenc-Voljc M, Pohar M, Lunder T. Density of Demodex folliculorum in perioral dermatitis. Acta Derm Venereol. 2005;85(3):211–5. (PMID: 1604040410.1080/00015550510030069)
Kaidbey KH, Kligman AM. The pathogenesis of topical steroid acne. J Invest Dermatol. 1974;62(1):31–6. (PMID: 427183810.1111/1523-1747.ep12676716)
Aucott JN. Glucocorticoids and infection. Endocrinol Metab Clin N Am. 1994;23(3):655–70. (PMID: 10.1016/S0889-8529(18)30091-4)
Choi E, Tan CL, Aw D. Malassezia: a case of coexisting pityriasis versicolor and Malassezia folliculitis. Singapore Med J. 2020;61(4):221. (PMID: 29926112790514310.11622/smedj.2018079) - Substance Nomenclature:
- 0 (Steroids)
- Entry Date(s):
- Date Created: 20210819 Date Completed: 20211001 Latest Revision: 20220303
- Update Code:
- 20240104
- PubMed Central ID:
- PMC8481181
- DOI:
- 10.1007/s40261-021-01072-z
- PMID:
- 34409577
- Czasopismo naukowe
Menu główne
Wyszukiwarka
Treść główna
